Get the Stockscreener App
31.96
2.57%
0.80
After Hours:
31.96
Enovis Corp stock is traded at $31.96, with a volume of 704.82K.
It is up +2.57% in the last 24 hours and down -18.45% over the past month.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
See More
Previous Close:
$31.16
Open:
$30.89
24h Volume:
704.82K
Relative Volume:
0.86
Market Cap:
$1.85B
Revenue:
$2.00B
Net Income/Loss:
$-119.19M
P/E Ratio:
-14.59
EPS:
-2.19
Net Cash Flow:
$-61.88M
1W Performance:
-0.44%
1M Performance:
-18.45%
6M Performance:
-22.16%
1Y Performance:
-43.17%
1-Day Range:
$30.89
$31.99
1-Week Range:
$30.61
$33.14
52-Week Range:
$29.32
$56.89
Enovis Corp Stock (ENOV) Company Profile
Name
Enovis Corp
Sector
Industry
Phone
(302) 252-9160
Address
2711 CENTERVILLE ROAD, WILMINGTON
Compare ENOV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENOV
Enovis Corp
|
31.96 | 1.85B | 2.00B | -119.19M | -61.88M | -2.19 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Enovis Corp Stock (ENOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Jun-13-24 | Initiated | JP Morgan | Neutral |
| Feb-13-24 | Initiated | Stephens | Overweight |
| Jan-22-24 | Initiated | UBS | Buy |
| Jan-03-24 | Initiated | William Blair | Outperform |
| Dec-15-23 | Reiterated | Needham | Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Jun-26-23 | Initiated | Needham | Buy |
| May-12-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-11-22 | Initiated | Goldman | Buy |
| Sep-12-22 | Initiated | Canaccord Genuity | Buy |
| Sep-12-22 | Initiated | Evercore ISI | Outperform |
| Jun-28-22 | Initiated | Argus | Hold |
| Jun-27-22 | Resumed | Loop Capital | Buy |
| Jun-16-22 | Initiated | Wells Fargo | Equal Weight |
View All
Enovis Corp Stock (ENOV) Latest News
Reasons to Sell ENOV and 1 Stock to Buy Instead - Yahoo Finance
Commit To Purchase Enovis At $25, Earn 10.7% Annualized Using Options - Nasdaq
Enovis to Host First Quarter 2025 Results Conference Call on May 8th - The Manila Times
Enovis to Host First Quarter 2025 Results Conference Call on May 8th | ENOV Stock News - GuruFocus
Enovis Corporation to Host Investor Conference Call for Q1 2025 Financial Results on May 8th - Nasdaq
Q1 2025 Earnings Preview: Enovis Readies Major Investor Update with Live Presentation May 8 - Stock Titan
Enovis Announces Third Quarter 2024 Results - ADVFN
Enovis’s Strategic Initiatives and Acquisitions Drive Buy Rating - TipRanks
Enovis names McDonald as CEO - MSN
Enovis appoints Damien McDonald as CEO - MedTech Dive
Enovis Appoints Damien McDonald CEO, Reaffirms Q1 Guidance Amid Strategic Growth Push - insights.citeline.com
Canaccord maintains Buy rating and $75 target for Enovis stock - Investing.com Australia
Enovis Receives Buy Rating Amidst Strategic Leadership Change and Strong Financial Projections - TipRanks
Canaccord maintains Buy rating and $75 target for Enovis stock By Investing.com - Investing.com India
Enovis’s Promising Future: Buy Rating Backed by Strategic Leadership and Positive Financial Outlook - TipRanks
Enovis names Damien McDonald as new CEO starting May 12 By Investing.com - Investing.com Canada
Enovis (ENOV) Appoints New CEO and Confirms Revenue Forecast - GuruFocus
Enovis Names Damien McDonald as New CEO to Drive Next Growth Chapter - MSN
Analysts Have Conflicting Sentiments on These Industrial Goods Companies: Enovis (ENOV) and Auckland International Airport Limited (OtherACKDF) - The Globe and Mail
Enovis names Damien McDonald as CEO, succeeding Matt Trerotola - TipRanks
Strategic Leadership and Financial Stability Drive Buy Rating for Enovis - TipRanks
Enovis Appoints Damien McDonald as New CEO - TipRanks
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer - Ortho Spine News
Enovis Corporation Reiterats Earnings Guidance for the First Quarter of 2025 - MarketScreener
Former LivaNova CEO to take corner office at Enovis - MassDevice
Enovis names Damien McDonald as new CEO starting May 12 - Investing.com Australia
Enovis Names Damien McDonald as Chief Executive; Reaffirms Q1 Revenue Guidance - MarketScreener
Enovis Appoints Damien McDonald as Chief Executive Officer - citybiz
Enovis Announces Appointment Of Damien Mcdonald As Chief Executive Officer - MarketScreener
Enovis Announces Appointment Of Damien McDonald As Chief Executive Officer - MarketScreener
Medical Device Expert Takes Helm at Enovis: Former LivaNova CEO to Drive Growth - Stock Titan
Enovis Corporation (NYSE:ENOV) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
2 Healthcare Stocks with Solid Fundamentals and 1 to Turn Down - The Globe and Mail
Enovis Showcases Innovative Foot and Ankle Solutions at ACFAS Conference - MSN
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025 - GlobeNewswire
Enovis, Foundation Surgical and J&J MedTech Named Winners of OMTEC® Awards, Honoring Excellence in Orthopedic Innovation - Ortho Spine News
Revolutionary Bunion Surgery System Leads Enovis's Major Product Launch at ACFAS 2025 - Stock Titan
Enovis : trade; Publishes 2024 Corporate Social Responsibility Report - MarketScreener
Enovis Corp (ENOV) Stock Price Up 1.77% on Mar 19 - GuruFocus.com
Enovis Plans Leadership Change - The Healthcare Technology Report.
Enovis CEO Matthew Trerotola Announces Retirement Plan - TipRanks
Positive Outlook for Enovis: Strong Market Position and Strategic Growth Initiatives - TipRanks
Diabetic Footwear Market Demand : Identifying Key Growth Opportunities By 2032 | Enovis companies, Pilgrim - EIN News
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MSN
Enovis Corp Stock (ENOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):